What is ORGS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ORGS?

P/E (TTM) is n/a and 52-week range is $0.00 to $1.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ORGS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ORGS?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-9.39B, EPS (TTM) near $-11.22 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Orgenesis Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Germantown, Maryland, US, 9.8M shares outstanding, ISIN US68619K3032 when available from company profile and filing metadata.

Orgenesis Inc

$ORGS

Health Care · Biotechnology

IR Run Scenarios

$0.35

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 77 full-time employees. The company went IPO on 2010-07-01. The firm focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. The company operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Employees

Website

www.orgenesis.com/

IPO

2010-07-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)